Orthocell Grants 263,895 Retention Rights and 99,264 Performance Rights to Employees Under Employee Awards Plan

Details of Orthocell’s Employee Incentive Rights Issuance

Orthocell Limited, an ASX-listed biomedical company, announced the issuance of 263,895 retention rights to employees effective 17 July 2026. These unquoted securities were granted under the company’s Employee Awards Plan, designed to attract and retain key personnel by providing equity compensation that vests over time based on continued employment. The retention rights issued rank equally with existing securities in the same class from the date of issue. Following this grant, Orthocell holds a total of 3,664,532 retention rights (OCCAAH) outstanding. Specific vesting conditions, exercise prices, and expiry terms were not disclosed but are governed by the Employee Awards Plan filed with the ASX in October 2025.

Performance Rights Allocation and Long-Term Incentives

Concurrently, Orthocell issued 99,264 performance rights (OCCAY) to an employee under the same plan. These rights are contingent on meeting defined performance criteria prior to conversion into ordinary shares, aligning employee rewards with company or individual achievements. After this issuance, the total performance rights outstanding reached 2,046,960. The performance rights rank equally with existing securities in their class and were allocated to key management personnel or associates, underscoring senior leadership’s participation in the incentive program. Details on performance conditions and vesting schedules are outlined in the Employee Awards Plan documentation.

Impact on Capital Structure and Unquoted Securities

This issuance expands Orthocell’s unquoted securities portfolio, which includes various options and rights with exercise prices ranging from $0.36 to $1.95 and expiry dates from April 2027 through October 2028. The company’s quoted capital comprises 272,253,637 fully paid ordinary shares, with approximately 24.8 million unquoted options and rights outstanding. This layered capital structure is typical for growth-stage biomedical firms, balancing cash preservation with employee incentivisation. Immediate dilution impact remains limited until conversion or exercise of these securities.

Regulatory Compliance and ASX Listing Rule Adherence

The grants were made under ASX Listing Rule 7.2 exception 13, allowing employee incentive securities to be issued without prior shareholder approval. This facilitates streamlined equity compensation while maintaining transparency through required regulatory disclosures. Orthocell fulfilled continuous disclosure obligations by lodging an Appendix 3G notification with the ASX, detailing the issuance and ensuring investor awareness.

Orthocell’s Business Strategy and Employee Equity Framework

Operating in the healthcare and biotechnology sectors, Orthocell leverages equity-based incentives to attract and retain highly skilled professionals essential for its research, development, and commercialisation efforts. The Employee Awards Plan incorporates retention rights to reward ongoing service and performance rights to incentivise achievement of specific milestones, supporting both workforce stability and strategic goal attainment. The plan’s comprehensive terms are publicly accessible via the ASX filings from October 2025.

Investor Perspective and Market Context

Issuance of employee incentive securities is a common practice among ASX-listed biotech companies and signals management’s confidence in Orthocell’s future. The mix of retention and performance rights aligns employee interests with shareholder value creation while managing dilution prudently. Investors should monitor the scale and timing of future equity grants to assess potential impacts on share capital and returns.

Retention Rights Vesting and Employee Commitment

Retention rights granted typically vest based on continued employment over a defined period, fostering employee loyalty during critical phases such as product development and regulatory milestones. The 263,895 retention rights issued increase Orthocell’s total retention rights to 3,664,532. While specific vesting terms were not disclosed, these are governed by the Employee Awards Plan and individual grant agreements, encouraging long-term employee commitment.

Performance Rights Conversion and Alignment with Company Goals

The 99,264 performance rights are conditional on achieving predetermined performance targets and convert directly into ordinary shares without an exercise price. Allocated to senior management, these rights align leadership incentives with measurable company success factors such as regulatory approvals, revenue growth, or operational improvements. Orthocell’s total performance rights outstanding now stand at 2,046,960.

Capital Efficiency and Future Share Issuance Pipeline

By issuing unquoted retention and performance rights rather than immediate share issuances, Orthocell preserves cash resources and limits dilution until vesting and conversion occur. The broad range of option exercise prices and expiry dates reflects a tailored incentive approach responsive to market conditions and company milestones. Investors should track conversion activity to gauge employee confidence and potential dilution effects.

Ongoing Disclosure and Corporate Governance

Orthocell complies with ASX continuous disclosure requirements by providing detailed notifications of unquoted securities issuances via Appendix 3G forms. The company’s transparency includes public access to the Employee Awards Plan terms, supporting informed investor assessment of equity incentive impacts. This routine disclosure does not indicate any changes to Orthocell’s strategic or financial position but reflects standard updates to its employee compensation program.